Teva Pharmaceutical Industries (NYSE:TEVA – Get Free Report)‘s stock had its “buy” rating reiterated by HC Wainwright in a research report issued to clients and investors on Tuesday, Benzinga reports. They currently have a $54.00 price objective on the stock. HC Wainwright‘s price target suggests a potential upside of 26.72% from the stock’s previous close.
TEVA has been the topic of a number of other reports. Piper Sandler lifted their price objective on Teva Pharmaceutical Industries from $44.00 to $56.00 and gave the stock an “overweight” rating in a research report on Thursday, November 12th. TD Cowen upped their target price on Teva Pharmaceutical Industries from $55.00 to $57.00 and gave the company a “buy” rating in a report on Wednesday, November 4th. Zacks Research lowered Teva Pharmaceutical Industries from a “hold” rating to a “strong sell” rating in a research note on Tuesday, October 20th. Leerink Partners lifted their price target on shares of Teva Pharmaceutical Industries from $45.00 to $52.00 and gave the company an “outperform” rating in a report on Thursday, November 5th. Finally, Weiss Ratings raised shares of Teva Pharmaceutical Industries from a “hold (c)” rating to a “hold (c+)” rating in a research report on Wednesday, November 4th. Thirteen equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $48.31.
Read Our Latest Analysis on Teva Pharmaceutical Industries
Teva Pharmaceutical Industries Stock Performance
Teva Pharmaceutical Industries stock opened at $42.61 on Tuesday. The company has a current ratio of 0.95, a quick ratio of 0.74 and a debt-to-equity ratio of 1.59. The firm has a 50-day moving average of $40.29 and a 200-day moving average of $35.12. The firm has a market cap of $49.66 billion, a P/E ratio of 99.10, a P/E/G ratio of 4.09 and a beta of 0.97. Teva Pharmaceutical Industries has a 1-year low of $24.01 and a 1-year high of $44.57.
Teva Pharmaceutical Industries (NYSE:TEVA – Get Free Report) last posted its earnings results on Tuesday, November 3rd. The company reported $0.86 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.72 by $0.14. Teva Pharmaceutical Industries had a return on equity of 33.20% and a net margin of 2.94%. The company had revenue of $4.39 billion for the quarter, compared to analysts’ expectations of $4.23 billion. During the same period last year, the firm earned $0.78 earnings per share. Teva Pharmaceutical Industries’s quarterly revenue was down 1.9% on a year-over-year basis. Sell-side analysts expect that Teva Pharmaceutical Industries will post 1.98 EPS for the current year.
Insider Transactions at Teva Pharmaceutical Industries
In related news, Director Roberto Mignone sold 367,600 shares of Teva Pharmaceutical Industries stock in a transaction that occurred on Friday, September 18th. The stock was sold at an average price of $39.06, for a total transaction of $14,358,456.00. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, EVP Richard Daniell sold 25,000 shares of the company’s stock in a transaction on Monday, November 9th. The stock was sold at an average price of $42.91, for a total value of $1,072,750.00. Following the completion of the sale, the executive vice president directly owned 55,755 shares in the company, valued at approximately $2,392,447.05. The trade was a 30.96% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last three months, insiders have sold 715,945 shares of company stock worth $29,061,351. 0.54% of the stock is owned by insiders.
Institutional Trading of Teva Pharmaceutical Industries
Hedge funds have recently modified their holdings of the business. Root Financial Partners LLC purchased a new stake in shares of Teva Pharmaceutical Industries in the 3rd quarter worth about $33,000. Western Wealth Management LLC purchased a new position in Teva Pharmaceutical Industries during the 1st quarter valued at about $43,000. Sunbelt Securities Inc. purchased a new position in Teva Pharmaceutical Industries during the 1st quarter valued at about $45,000. CX Institutional bought a new stake in Teva Pharmaceutical Industries during the second quarter worth about $54,000. Finally, EverSource Wealth Advisors LLC boosted its stake in Teva Pharmaceutical Industries by 64.0% during the first quarter. EverSource Wealth Advisors LLC now owns 1,658 shares of the company’s stock worth $50,000 after acquiring an additional 647 shares in the last quarter. Institutional investors own 54.05% of the company’s stock.
About Teva Pharmaceutical Industries
Teva Pharmaceutical Industries is a global pharmaceutical company that develops, manufactures and markets generic medicines, specialty medicines and biosimilars. Its portfolio spans treatments for conditions including neurological disorders, respiratory diseases and cancer, alongside a broad range of generic medicines across therapeutic areas. Founded in Jerusalem in 1901, Teva has grown from a regional pharmaceutical business into an international company. It serves patients and healthcare providers in markets around the world, including North America, Europe and other regions.
Featured Articles
- Five stocks we like better than Teva Pharmaceutical Industries
- MongoDB’s Biggest Advantage May Be GitLab’s Biggest Weakness
- Ondas Is Building a Defense Growth Engine, But Can It Deliver on Its Backlog?
- Orbiting Growth: Federal Contracts Boost Viasat’s Outlook
- Modine Manufacturing Scales Up to Solve the AI Heat Problem
Receive News & Ratings for Teva Pharmaceutical Industries Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries and related companies with MarketBeat.com's FREE daily email newsletter.
